Roberta Vene
Overview
Explore the profile of Roberta Vene including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1035
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Costa D, Vene R, Coco S, Longo L, Tosetti F, Scabini S, et al.
Cells
. 2023 Feb;
12(4).
PMID: 36831331
The p38 inhibitor SB202190 is a necessary component of the medium used for normal colorectal mucosa cultures. Sato et al. suggested that the primary activity of SB202190 may be EGFR...
2.
Miano M, Madeo A, Cappelli E, Lanza F, Lanza T, Stroppiano M, et al.
J Allergy Clin Immunol Pract
. 2020 Jul;
8(10):3535-3542.
PMID: 32702516
Background: Gaucher disease (GD) is a rare disorder characterized by defective function of β-glucocerebrosidase, which leads to progressive accumulation of its substrate in various organs, particularly the mononuclear phagocyte system....
3.
Barboro P, Benelli R, Tosetti F, Costa D, Capaia M, Astigiano S, et al.
Carcinogenesis
. 2020 Jun;
41(9):1246-1252.
PMID: 32525968
Castration-resistant prostate cancer (CRPC) is an incurable stage of the disease. A multivariate principal component analysis on CRPC in vitro models identified aspartyl (asparaginyl) β hydrolase (ASPH) as the most...
4.
Vene R, Costa D, Augugliaro R, Carlone S, Scabini S, Pattacini G, et al.
Cells
. 2020 Mar;
9(3).
PMID: 32168749
Observational/retrospective studies indicate that prostaglandin-endoperoxide synthase-2 (PTGS2) inhibitors could positively affect colorectal cancer (CRC) patients' survival after diagnosis. To obtain an acceptable cost/benefit balance, the inclusion of PTGS2 inhibitors in...
5.
Carrega P, Orecchia P, Quatrini L, Tumino N, Vene R, Benelli R, et al.
Gut
. 2020 Mar;
69(12):2261-2263.
PMID: 32139551
No abstract available.
6.
Miano M, Cappelli E, Pezzulla A, Vene R, Grossi A, Terranova P, et al.
Br J Haematol
. 2019 Jul;
187(4):502-508.
PMID: 31309545
Autoimmune lymphoproliferative syndrome (ALPS) is a congenital disorder that results in an apoptosis impairment of lymphocytes, leading to chronic lymphoproliferation and autoimmunity, mainly autoimmune cytopenias. FAS gene defects are often...
7.
Pistillo M, Carosio R, Banelli B, Morabito A, Mastracci L, Ferro P, et al.
Cell Mol Immunol
. 2019 Jun;
17(4):410-411.
PMID: 31217525
No abstract available.
8.
Poggi A, Benelli R, Vene R, Costa D, Ferrari N, Tosetti F, et al.
Front Immunol
. 2019 May;
10:961.
PMID: 31130953
It is well established that natural killer (NK) cells are involved in both innate and adaptive immunity. Indeed, they can recognize molecules induced at the cell surface by stress signals...
9.
Costa D, Vene R, Benelli R, Romairone E, Scabini S, Catellani S, et al.
Front Immunol
. 2018 Jun;
9:1150.
PMID: 29910806
Mesenchymal stromal cells (MSC) present in the tumor microenvironment [usually named tumor-associated fibroblasts (TAF)] can exert immunosuppressive effects on T and natural killer (NK) lymphocytes, favoring tumor immune escape. We...
10.
Tosetti F, Vene R, Camodeca C, Nuti E, Rossello A, DArrigo C, et al.
Oncoimmunology
. 2018 May;
7(5):e1421889.
PMID: 29721369
Shedding of ADAM10 substrates, like TNFα, MICA or CD30, is reported to affect both anti-tumor immune response and antibody-drug-conjugate (ADC)-based immunotherapy. Soluble forms of these molecules and ADAM10 can be...